ArticleCancer research communications2026
Intravenous Immunoglobulin Reduces Infections for Patients with Chronic Lymphocytic Leukemia: A Single-Center Retrospective Analysis.
Article in Cancer research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Hypogammaglobulinemia is common in patients with chronic lymphocytic leukemia (CLL). Prior studies demonstrated that intravenous immunoglobulin (IVIG) reduced infections without survival benefit. We conducted a single-institution retrospective cohort study of infectious outcomes in patients with CLL who received IVIG between 2005 and 2022 to assess the impact of IVIG across evolving CLL treatment paradigms, including the introduction of targeted agents. Fifty-two patients met the inclusion criteria of IVIG use for hypogammaglobulinemia and recurrent infections, with also any infection up to 1 year prior to the initiation of IVIG. Baseline mean IgG prior to IVIG was 389 mg/dL (range, 93-891 mg/dL). By design, all 52 patients (100%) experienced at least one CTCAE grade ≥2 infection in the 12 months prior to IVIG initiation. In the 12 months following IVIG initiation, only 17 patients (33%) experienced a grade ≥2 infection. IVIG therapy was associated with a 67% reduction in risk of grade 2 infections (RR 0.33; 95% confidence interval, 0.22-0.48; P < 0.0001), corresponding to an absolute risk reduction of 67% and a number needed to treat of 1.5. The mean number of infections per patient also reduced from 2.1 to 0.4. Baseline IgA and IgG levels, as well as recent CLL treatment, were not predictors of residual post-IVIG infections. These findings suggest that IVIG may yield meaningful improvements in patient quality of life by reducing infections. SIGNIFICANCE: Hypogammaglobulinemia and recurrent infections remain a complication of CLL, despite contemporary agents. In this 2005 to 2022 retrospective cohort, IVIG initiation was associated with a large reduction in CTCAE grade ≥2 infections: only 33% of patients had a post-IVIG grade ≥2 infection versus all patients before IVIG. Residual infections were not explained by baseline IgG/IgA levels or recent therapy. IVIG may be an effective supportive-care strategy in patients with CLL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.